Extract

To compare standard treatment, low-dose Ara-C against the available novel approaches: •LD Ara-C combined with AC220 •LD Ara-C combined with Ganetespib •LD Ara-C combined with Tosedostat •LD Ara-C combined with Selinexor •Drug X During the course of the Programme other novel therapies (Drug X) are expected to become available, and will be considered for inclusion in this comparison.

Inclusion criteria

• Acute myeloid leukemia and high-risk myelodysplastic syndrome

Links

• isrctn
• ictrp
• euctr
• ictrp
• ictrp
• euctr